Noah AI Industry News

Delivers real-time biopharma news and signals — powered by AI, curated for professionals.

Roche and Jazz Pharmaceuticals Announce Promising Results in Phase III Lung Cancer Trial

Roche and Jazz Pharmaceuticals Announce Promising Results in Phase III Lung Cancer Trial

Roche and Jazz Pharmaceuticals have unveiled updated Phase III data for a combination therapy of their drugs Tecentriq and Zepzelca, demonstrating improved survival rates in small cell lung cancer (SCLC) patients. The results, presented at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting and published in The Lancet, have bolstered the companies' plans to seek FDA approval for the drug combination in first-line maintenance therapy for SCLC.

NoahAI News6/4/2025
Bayer's Elinzanetant Shows Promise in Alleviating Breast Cancer Treatment Side Effects

Bayer's Elinzanetant Shows Promise in Alleviating Breast Cancer Treatment Side Effects

Bayer has unveiled promising results for its experimental drug elinzanetant, demonstrating its potential to address a significant unmet need in breast cancer treatment. The non-hormonal medication has shown efficacy in reducing vasomotor symptoms associated with endocrine therapy, a common treatment for hormone receptor-positive breast cancer.

NoahAI News6/4/2025
Hims & Hers Expands into European Market with Zava Acquisition

Hims & Hers Expands into European Market with Zava Acquisition

Telehealth company Hims & Hers Health, Inc. has announced its intention to acquire European digital healthcare provider Zava in an all-cash deal, marking a significant step in the company's international expansion strategy. The acquisition, expected to close in the second half of 2025, will bring Hims & Hers to over a million customers in the European market and launch its services for the first time in Germany, France, and Ireland, while also expanding its presence in the UK.

NoahAI News6/4/2025
J&J's Akeega Shows Promise in Earlier-Stage Prostate Cancer Treatment

J&J's Akeega Shows Promise in Earlier-Stage Prostate Cancer Treatment

Johnson & Johnson's combination drug Akeega has demonstrated significant efficacy in treating earlier-stage prostate cancer patients with certain genetic mutations, according to new data presented at the American Society of Clinical Oncology (ASCO) annual meeting in Chicago. The results from the Phase 3 Amplitude trial suggest potential for expanded use of the drug, which is currently approved only for advanced, castration-resistant prostate cancer with BRCA mutations.

NoahAI News6/4/2025
Trump Administration Appoints New National Coordinator for Health IT

Trump Administration Appoints New National Coordinator for Health IT

The Trump administration has named Thomas Keane as the new national coordinator for health information technology, marking a significant change in leadership for the federal government's health IT efforts. Keane, a software engineer and interventional radiologist, assumed the role on Monday, according to a spokesperson for the Assistant Secretary for Technology Policy/Office of the National Coordinator for Health IT (ASTP/ONC).

NoahAI News6/4/2025
Merck's $3B+ Bid for MoonLake Signals Shift in Late-Phase Biotech Landscape

Merck's $3B+ Bid for MoonLake Signals Shift in Late-Phase Biotech Landscape

Merck & Co., facing the looming loss of exclusivity for its blockbuster cancer drug Keytruda, has reportedly made a bold move to diversify its portfolio. The pharmaceutical giant offered over $3 billion to acquire MoonLake Immunotherapeutics, a late-phase biotech company specializing in inflammatory diseases. This development, reported by the Financial Times, marks a significant shift in Merck's strategy and could potentially reshape the late-phase biotech landscape.

NoahAI News6/4/2025
Transpire Bio Licenses Inhaled PDE4 Inhibitor for Idiopathic Pulmonary Fibrosis Treatment

Transpire Bio Licenses Inhaled PDE4 Inhibitor for Idiopathic Pulmonary Fibrosis Treatment

Transpire Bio, a Florida-based pharmaceutical company, has entered into a licensing agreement with China's Intragrand Pharma for an inhaled PDE4 inhibitor, lenamilast (ITG-1052), as a potential treatment for idiopathic pulmonary fibrosis (IPF). The deal, announced on June 3, 2025, grants Transpire Bio the ex-China rights to the drug, positioning the company to compete in the growing market for IPF therapies.

NoahAI News6/4/2025
Agenus Inks $141M Deal with Zydus, Transfers California Manufacturing Plants

Agenus Inks $141M Deal with Zydus, Transfers California Manufacturing Plants

Agenus, a Massachusetts-based biotech company, has entered into a strategic partnership with Indian drugmaker Zydus Lifesciences, valued at up to $141 million. The deal, announced on June 3, 2025, involves the transfer of two California manufacturing facilities to Zydus and aims to accelerate the development of Agenus' cancer combination therapy.

NoahAI News6/4/2025
H1 Acquires Veda Data Solutions to Enhance Provider Data Accuracy in Healthcare

H1 Acquires Veda Data Solutions to Enhance Provider Data Accuracy in Healthcare

H1, a leading healthcare technology company, has announced the acquisition of Veda Data Solutions, a move aimed at strengthening its provider data and automation solutions for health plans. This strategic acquisition comes just five months after H1's purchase of Ribbon Health, signaling the company's aggressive expansion in the healthcare data management sector.

NoahAI News6/4/2025
HHS Under Fire for Controversial Workforce Reduction and Privacy Violations

HHS Under Fire for Controversial Workforce Reduction and Privacy Violations

The Department of Health and Human Services (HHS) faces significant legal challenges following a major workforce reduction and alleged mishandling of personnel records. A new class action lawsuit claims that HHS and the Department of Government Efficiency (DOGE) violated federal privacy laws during the recent layoffs, which saw approximately 10,000 workers lose their jobs.

NoahAI News6/4/2025
OSE Immunotherapeutics Reports Promising Results for Cancer Vaccine in Phase 2 Pancreatic Cancer Trial

OSE Immunotherapeutics Reports Promising Results for Cancer Vaccine in Phase 2 Pancreatic Cancer Trial

OSE Immunotherapeutics, a French biotech company, has unveiled encouraging data from its phase 2 clinical trial evaluating Tedopi, a therapeutic cancer vaccine, in combination with chemotherapy for advanced or metastatic pancreatic ductal adenocarcinoma (PDAC). The results, presented at the American Society of Clinical Oncology (ASCO) meeting, demonstrate a significant improvement in overall survival rates compared to chemotherapy alone.

NoahAI News6/4/2025
Eli Lilly Partners with Camurus to Develop Long-Acting Obesity and Diabetes Treatments in $870M Deal

Eli Lilly Partners with Camurus to Develop Long-Acting Obesity and Diabetes Treatments in $870M Deal

Eli Lilly has entered into a licensing agreement with Swedish pharmaceutical company Camurus, leveraging the latter's FluidCrystal technology to develop long-acting formulations of its incretin-based compounds for obesity and diabetes. The deal, which could be worth up to $870 million, signifies Lilly's commitment to expanding its portfolio in the rapidly growing cardiometabolic health space.

NoahAI News6/4/2025
«1...596061...67»